This site is intended for Healthcare Professionals only.

CPE raises concern on availability and pricing issues of Atorvastatin tablets

Date:

Share post:

The Community Pharmacy England has raised a concern on pricing and availability of Atorvastatin tablets.

CPE is In discussions with the Department of Health and Social Care (DHSC) and have warned about the serious impact this issue is now having on pharmacies.

The issue was highlighted after a number of pharmacy owners have got in touch with CPE about the pricing and availability of Atorvastatin tablets.

The association said: “The DHSC Supply Team has been working closely with manufacturers and wholesalers on this issue.

Thank you to those of you who have taken the time to report the increased prices that you have purchased at.

We will continue to use these reports to highlight just how much of an impact this is having on pharmacies who are desperately trying to get hold of limited stock and having to pay inflated prices for it without any certainty of their final reimbursement prices.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue March 2024

Related articles

Boots supports community pharmacists become Mental Health First Aiders

PDA encourages representatives at Boots to undertake Mental Health First Aid (MHFA) training Pharmacists, who are working on the...

Surge in stroke cases could cost UK £75bn by 2035, charity warns

By 2035, there will be 151,000 hospital admissions due to stroke every year, averaging 414 admissions per day...

NHS and i.AI forge historic collaboration to boost healthcare

AI assisting NHS to half treatment times for stroke patients and overall patient care experience The Department of Health...

NHS to cut the red tape to support 50K NHS postgraduate doctors

New measures are part of NHS' broader efforts to retain its skilled workforce and ensure high-quality patient care  In...